Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001178913-24-003686
Filing Date
2024-11-14
Accepted
2024-11-14 08:30:59
Documents
63
Period of Report
2024-09-30

Document Format Files

Seq Description Document Type Size
1 10-Q zk2432270.htm   iXBRL 10-Q 1882593
2 EXHIBIT 31.1 exhibit_31-1.htm EX-31.1 14992
3 EXHIBIT 31.2 exhibit_31-2.htm EX-31.2 15049
4 EXHIBIT 32.1 exhibit_32-1.htm EX-32.1 6969
5 EXHIBIT 32.2 exhibit_32-2.htm EX-32.2 6753
  Complete submission text file 0001178913-24-003686.txt   8207656

Data Files

Seq Description Document Type Size
6 XBRL SCHEMA FILE slxn-20240930.xsd EX-101.SCH 126923
7 XBRL CALCULATION FILE slxn-20240930_cal.xml EX-101.CAL 34955
8 XBRL DEFINITION FILE slxn-20240930_def.xml EX-101.DEF 274495
9 XBRL LABEL FILE slxn-20240930_lab.xml EX-101.LAB 1307379
10 XBRL PRESENTATION FILE slxn-20240930_pre.xml EX-101.PRE 354211
66 EXTRACTED XBRL INSTANCE DOCUMENT zk2432270_htm.xml XML 1151339
Mailing Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606
Business Address 12 ABBA HILLEL ROAD RAMAT GAN L3 5250606 972-8-6286005
Silexion Therapeutics Corp (Filer) CIK: 0002022416 (see all company filings)

EIN.: 000000000 | State of Incorp.: E9 | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-42253 | Film No.: 241457391
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)